Abstract

Lyme borreliosis (LB) is a multisystem infectious disease abundant in the northern countries of the world and is caused by Borrelia species. Vaccination against LB is an effective way to prevent and reduce the number of diseases in endemic areas. Several vaccines have been developed and tested in the past, but no human LB vaccine is currently available on the market. This review aims to uncover and delineate various strategies and diverse technological approaches related to vaccine production. Furthermore, we characterize already tested vaccines, possibilities for their future development, and reasons for their failure.

Details

Title
Vaccines for Lyme Borreliosis: Facts and Challenges
Author
Bodnárová, S 1 ; Čížková, D 2 ; Hudáková, N 2 ; Mangesh, Bhide M 3 

 Faculty of Medicine, Pavol Jozef Safarik University in Košice, Rastislavova 43, 041 90 Košice 
 Centre of Experimental and Clinical Regenerative Medicine 
 Laboratory of biomedical microbiology and immunology, University of Veterinary Medicine and Pharmacy, Komenského 73, 041 81, Košice, Slovakia 
Pages
49-59
Publication year
2022
Publication date
2022
Publisher
De Gruyter Poland
ISSN
00155748
e-ISSN
24537837
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3156522804
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.